GLP-1 drugs could be one of the most significant advances in treating chronic disease in decades. They also have the potential to become one of the most expensive items employers have ever had to pay for in their health plans, and more employers are reporting that the costs of GLP-1 coverage is a lot more than they ever expected. There are ways, however, to ensure that the money spent leads to better outcomes.
The first question employers should ask: Should we cover them? I would argue that’s actually the wrong question. The better question to ask is: If we are going to cover GLP-1 drugs, how can we ensure that we aren’t simply throwing our money away? How do we ensure that the dollars we spend on GLP-1 drugs lead to sustainable health benefits rather than millions of dollars of abandoned treatment? Because when you think about it, there is no such thing as “the employer paying.” The employee is paying as well. Through premiums, deductibles, copays, and, indirectly, through the impact that soaring healthcare costs have on wages and other benefits. And the costs are becoming hard to ignore.
The GLP-1 bill is arriving
Employers have been warming up to covering obesity drugs. Three-in-ten large employers covered GLP-1 drugs for weight loss as their primary purpose in 2024, up from 28% the year prior, KFF reported.
Of employers offering that benefit, nearly a third required enrollees to also participate in a lifestyle program or have meetings with a nutritionist, case manager or therapist. Those numbers are shifting.
Drug costs are rising about 9%. Among large employers, 6% dropped coverage of GLP-1 drugs for weight loss this year, Mercer found. An additional 25% will drop coverage next year or are considering it.
Another 27% tightened utilization controls or say they will. That’s the natural reaction when pharmacy spend infringes on benefit budgets. But drug coverage doesn’t just go away. Obesity isn’t cured because the formulary doesn’t include obesity medications. Diabetes, heart disease, sleep apnea, musculoskeletal conditions, and other obesity-related ailments are still there. Employers are just deciding where, when, and how they want to pay.
But there’s an even bigger problem: dropout
This is the other half of the GLP-1 story that needs much more attention.
Clinical trials have shown us these drugs work amazingly well under ideal conditions. Real-world persistence paints a much grimmer picture. When Prime Therapeutics looked at commercially insured adults without diabetes who initiated GLP-1 therapy for obesity, just 8% were still on treatment after three years. Even the pricey newer high-potency obesity drugs like Wegovy aren’t doing much better: three-year persistence was only 14%.
Newer cohorts are faring better in the first year: one-year persistence among individuals starting high-potency GLP-1s increased from 33% for those who initiated in 2021 to 63% for those who initiated in early 2024. That’s good news. Unfortunately, it doesn’t change the basic economic reality. What does an employer gain when an employee initiates an expensive chronic therapy and then stops taking it? This isn’t a critique of GLP-1s. It’s a critique of unmanaged GLP-1 coverage.
GLP-1 program dropout rates are high, with up to 65% of patients discontinuing within a year, particularly those treated for weight loss. While cost and side effects are factors, the lack of support and early feedback on progress are more significant drivers of discontinuation. Behavioral, trigger-based outreach can help identify and re-engage patients at risk of dropping out, improving program retention and revenue.

Stopping matters because the biology doesn’t stop
Here’s another sobering data point.
In STEP 1 extension, individuals on semaglutide lost an average of 17.3% of their body weight while on treatment. Twelve months after stopping treatment, they had regained about two- thirds of their weight loss. Many of the cardiometabolic benefits also reverted toward baseline levels.
Picture what that looks like to an employer. The company spends thousands of dollars on treatment to help an employee lose a significant amount of weight. The employee discontinues treatment and regains the weight. Some of the health benefits they achieved are now lost. And the plan will likely start spending money again on hypertension, diabetes, cardiovascular disease, and other obesity-related conditions it was hoping to prevent through successful treatment. That is not a very attractive revolving door.

So perhaps coverage shouldn’t simply mean “we pay for the drug”
Employers should stop approaching GLP-1 coverage as a pharmacy-benefit decision. Instead, they should evaluate it as part of their long-term cardiometabolic health strategy. That starts with coverage tied to conditions designed to maximize persistence and improve outcomes—not to create barriers that keep consumers from accessing prescriptions.
Before starting therapy, patients need realistic counseling about potential side effects, likely weight loss, the possibility of long-term therapy, and the consequences of stopping treatment. While on treatment, employers should offer access to nutrition counseling, behavioral interventions, and appropriate clinical follow-up. And plans should track something PBMs have historically been terrible at: outcomes. Not fills. Not rebates. Not gross-to-net dollars. Outcomes. Are employees remaining on therapy? If they remain on therapy, are they losing weight? Is weight loss clinically meaningful? Are employees’ blood pressure, glucose, and other cardiometabolic markers improving? Why do people drop off therapy? Are they stopping GLP-1s because of side effects? Is it cost? Has coverage changed? Are they experiencing access issues? Or is the medication simply not working? What happens to members after discontinuation?
Employers also need an exit strategy
This may be the most forgotten element of GLP-1 benefit design. Everyone has an initiation strategy. Prior authorization. BMI requirements. Step therapy. But what is the plan when someone stops? Simply turning off the prescription and wishing them well makes little sense.
If patients are going to stop GLP-1 treatment (and they will), employers should think just as creatively about weight-maintenance programs after treatment as they do about authorization before treatment. Nutrition. Resistance training/physical activity. Behavioral support. Frequent weight tracking. Clinical follow-up. Rapid response when meaningful weight regain is detected. Possible reinitiation or switch to alternate therapy if indicated. The objective shouldn’t be keeping everyone on a GLP-1 forever. The objective should be making sure the investment you’ve already made in that person’s health doesn’t go to waste.
And remember who ultimately pays
I know it’s tempting to view GLP-1 coverage as a battle between pharma and employers. It’s not. The employee who isn’t on a GLP-1 has a seat at the table, too. When pharmacy spending goes up dramatically, employers eventually need to balance that budget by capturing dollars from somewhere.
According to Mercer, 47% of large employers plan to make changes to their medical plans in 20A that will result in employees paying more out-of-pocket costs. That isn’t to say GLP-1 spends are single-handedly responsible for soaring deductibles and premiums.
When dollars are wasted, employers and plan members feel the impact through that same finite benefit budget. The employee on Wegovy pays. The employee not on Wegovy pays. Employers pay. That’s why I don’t believe unrestricted coverage is always compassionate—nor do I believe across-the-board exclusions are prudent. Somewhere in the middle is a solution.
Cover the appropriate patients. Negotiate aggressively on net price. Manage side effects early to prevent abandonment. Measure persistence AND clinical outcomes. Encourage lifestyle change for the duration of treatment. Have a REAL plan for when patients discontinue. And hold vendors accountable for those results—not just enrollment. Nobody is debating that GLP-1 drugs work on a chemical level to produce weight loss. The only question employers need to ask now is whether they can convert that science into sustainable real-world outcomes. Because the biggest waste may not come from paying for GLP-1 drugs. It may come from paying for them without consequences if employees stop taking them.

